<DOC>
	<DOC>NCT00894660</DOC>
	<brief_summary>The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).</brief_summary>
	<brief_title>A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. BMI of 18 to 30 kg/m2; and a total body weight &gt;45 kg (99 lbs). An informed consent document signed and dated by the subject or a legally acceptable representative. Evidence or history of clinically significant abnormalities. A positive urine drug screen, history of regular alcohol consumption.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Bioequivalence, Healthy Volunteers</keyword>
</DOC>